trending Market Intelligence /marketintelligence/en/news-insights/trending/ut_cg7_gloklfjvroatulg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Novo Nordisk to update prescription label of diabetes drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Novo Nordisk to update prescription label of diabetes drug

Novo Nordisk A/S said it received the U.S. Food and Drug Administration's approval to update the prescription label of its diabetes medicine Tresiba.

The updated label will reflect results from the Devote study, which showed that Tresiba was less likely to cause hypoglycemia in type 2 diabetes patients when compared to Sanofi's Lantus.

Hypoglycemia, commonly caused by medications to treat diabetes, is characterized by abnormally low blood glucose, which results in a variety of symptoms such as clumsiness, trouble talking and, in extreme cases, unconsciousness and death.

The label will also now indicate that Tresiba is just as safe as Lantus in patients at risk of having major adverse cardiovascular events, such as a heart attack or a stroke.